ABOUT BLOCK PAIN RECEPTORS WITH PROLEVIATE

Getting recognized the palmitoylation motif of APLNR, we developed a short substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This aggressive peptide, which targets the APLNR palmitoylation web site together with morphine, can inhibit the event of NCP, like pain incidence, microglial activation, and inflammatory asp